| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation (NCT04781855) | M.D. Anderson Cancer Center | 2022-07-14 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome (NCT04978779) | Vincerx Pharma, Inc. | 2021-12-16 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation (NCT04679012) | Weill Medical College of Cornell University | 2021-09-24 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma (NCT03892044) | David Bond, MD | 2019-11-05 |
| A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome (NCT03899337) | University of Birmingham | 2019-07-23 |
| BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation (NCT03931642) | French Innovative Leukemia Organisation | 2019-07-05 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643) | National Cancer Institute (NCI) | 2018-09-18 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (NCT03534323) | Dana-Farber Cancer Institute | 2018-07-12 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| Genomic and Proteomic Study of Richter Syndrome (CGPSR) (NCT03619512) | Central Hospital, Nancy, France | 2017-09-06 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients (NCT03145480) | Northwell Health | 2017-06-19 |
| A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome (NCT03054896) | Dana-Farber Cancer Institute | 2017-03-08 |
| Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (NCT02846623) | M.D. Anderson Cancer Center | 2017-01-31 |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia (NCT02530515) | M.D. Anderson Cancer Center | 2015-12-18 |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) (NCT02576990) | Merck Sharp & Dohme LLC | 2015-12-02 |
| Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation (NCT02535286) | TG Therapeutics, Inc. | 2015-09-18 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation (NCT02420912) | M.D. Anderson Cancer Center | 2015-06-19 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980) | Mayo Clinic | 2015-02-19 |
| Allogeneic Stem Cell Transplant for CLL (NCT01629511) | M.D. Anderson Cancer Center | 2012-11-21 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |